文献速递肾小球疾病

Felzartamab治疗利妥昔单抗抵抗性原发性膜性肾病的前瞻性队列研究

Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy.
PubMed 文献 · Kidney Int Rep · 2026-03-12

这项前瞻性单臂单中心开放标签试验纳入10例利妥昔单抗抵抗性肾病综合征的原发性膜性肾病患者,接受5个月9剂16 mg/kg felzartamab输注并随访24个月。主要终点12个月24小时蛋白尿与基线相似,抗PLA2R抗体仅短暂下降未耗竭,治疗安全但无效。

要点

  • Felzartamab在利妥昔单抗抵抗性原发性膜性肾病患者中安全耐受良好。
  • 12个月24小时蛋白尿与基线相似,主要终点未达到。
  • 抗PLA2R抗体短暂下降但从未耗竭,NK和B细胞深度持续减少。

核心结论

  • 一疗程felzartamab安全耐受良好,但在膜性肾病合并利妥昔单抗抵抗性肾病综合征患者中无效。

研究设计与样本

  • 前瞻性单臂单中心开放标签试验,纳入10例白人成年患者,估算GFR>30 ml/min/1.73 m2。

主要发现

  • 12个月24小时蛋白尿与基线相似。
  • 线性混合模型分析显示24小时蛋白尿和白蛋白尿无显著时间依赖性变化。
  • 血清总蛋白、白蛋白、肌酐和血脂水平、GFR及白蛋白分数清除率无显著时间依赖性变化。
  • 循环抗PLA2R抗体短暂下降但从未耗竭。
  • 所有考虑的Ig短暂下降至第12个月,之后恢复至基线。

关键数值与推荐

  • 主要终点为12个月时24小时蛋白尿(3次连续测量的中位数)。
  • Felzartamab剂量为16 mg/kg,5个月内9剂。
  • 纳入标准包括估算GFR>30 ml/min/1.73 m2。

临床怎么用

  • Felzartamab不推荐用于利妥昔单抗抵抗性原发性膜性肾病合并肾病综合征的患者。

局限性

  • 单臂、单中心、开放标签设计,样本量10例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Approximately 30% of patients with primary membranous nephropathy (MN) and nephrotic syndrome (NS) fail rituximab treatment through mechanisms that could be overcome by the human IgG1 monoclonal anti-CD38 antibody, felzartamab. METHODS: In this prospective, single-arm, single-center, open-label trial, 10 consenting Caucasian adult patients with MN, rituximab-resistant NS, and estimated glomerular filtration rate (GFR) > 30 ml/min per 1.73 m2 received a 5-month, 9-dose course of 16 mg/kg felzartamab infusions at the Nephrology Unit of Bergamo Hospital, Italy between November 9, 2021 and February 1, 2023 and were followed up with for 24 months. Clinical and laboratory parameters were evaluated at baseline, 1, 2, 5, 6, 9, 18, and 24 months, whereas GFR as well as albumin and IgG fractional clearances were measured at baseline and at 6, 9, 12, 18, and 24 months posttreatment. The primary outcome was 24-hour proteinuria (median of 3 consecutive measurements) at 12 months. RESULTS: Twelve-month 24-hour proteinuria was similar to baseline. Linear-mixed model analyses showed no significant time-dependent changes in 24-hour proteinuria and albuminuria; serum total-protein, albumin, creatinine and lipid levels, GFR and albumin fractional clearances. Circulating anti-phospholipase A2 receptor (PLA2R) antibodies transiently decreased but were never depleted. All considered Igs transiently decreased up to month 12, and recovered to baseline thereafter. Felzartamab deeply and persistently decreased natural killer (NK), B cells, and antigen-inexperienced transitional B cells; however, it did not affect CD20-expressing memory B cells, plasmablasts, and plasma cells. Treatment was safe and well-tolerated. CONCLUSION: One course of felzartamab was safe and well-tolerated, but ineffective in patients with MN and rituximab-resistant NS, possibly because of the inability to persistently deplete nephritogenic autoantibody-producing CD38-expressing B cells.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Trillini M, Casiraghi F, Gennarini A, et al. Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy. Kidney Int Rep. 2026. PMID: 42027554. doi:10.1016/j.ekir.2026.106468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。